Valuing Drugs In The US: How We're Doing And What's Ahead

23 Jan 2018

Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.

In the US, efforts to incorporate a consideration of value into decisions about prescription drug reimbursement are expected to advance to a new phase in 2018, driven by payers and employers sponsoring insurance for their workers.

The move to consider value has been spurred by the development of several value frameworks over the past three years...